ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation

Contributed by: Business Wire

Logo

Images

(Photo: Business Wire)

Business Wire embedded0

Tags

Research

Neurology

Cannabis

Clinical Trials

Biotechnology

Health

Pharmaceutical

Science

Natural Resources

Nantheia ATL5 for Smoking Cessation

More Like This

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment

First Cannabis full-spectrum product, manufactured in Brazil by Ease Labs, is approved by the local Health Regulatory Agency

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States